Golden Biotechnology Corp (GBC, 國鼎) plans to apply for emergency use authorization in the US for its experimental COVID-19 drug after positive results in its phase 2 clinical trials, the company said.
GBC on Wednesday announced some of the results from randomized, double-blind and placebo-controlled studies in phase 2 clinical trials of its COVID-19 oral drug antroquinonol, dubbed Hocena, for the treatment of people hospitalized with mild-to-moderate COVID-19 symptoms.
In the trials, 97.9 percent of people recovered by the 14th day after being given the drug and all participants recovered by the 28th day, GBC spokesman Alan Tseng (曾木增) said yesterday.
Photo: Chen Yung-chi, Taipei Times
“Recovered” meant that participants did not have respiratory failure, and thus did not require ventilation, high-flow oxygen or extracorporeal membrane oxygenation, Tseng said.
The median length of hospitalization for those in the experimental group was four days, 20 percent shorter than for those in the control group, the company said.
Of the five participants in intensive care due to serious COVID-19 symptoms, the median length of treatment for those given the drug was 13.5 days, 9.5 days shorter than for those given the placebo, it said.
The median period in which those in the experimental group first tested negative for COVID-19 after receiving the drug was 14 days, the company said.
The full test results would be disclosed after GBC receives a report from Labcorp Drug Development, a US-based contract research organization that helped conduct the human trials, the company said.
The trials began in October 2020 and were conducted in Argentina, Peru and the US, it said.
GBC recruited 124 participants, despite initially planning to enroll 174.
“But the results of phase 2 clinical trials should be meaningful statistically once the number of participants exceeds 100,” GBC chairman Liu Sheng-yung (劉勝勇) said.
“Over the past year, the coronavirus mutated quickly and we have witnessed breakthrough infections, which occur when a fully vaccinated person contracts the disease,” Liu said, adding that the ratio of people with breakthrough infections to all of those infected with COVID-19 had surpassed 60 percent and is expected to continue rising.
“However, so far, no company has claimed that its drug can repel breakthrough infections, so we think it is necessary to test our drug against breakthrough infections in our phase 3 clinical trials,” Liu said. “So we are under time pressure” to finish phase 2 trials and begin phase 3.
GBC was the nation’s second biotech company to complete phase 2 human trials on an oral COVID-19 treatment, after Senhwa Biosciences Inc (生華科) in October last year.
GBC shares yesterday surged 50 percent to NT$212.22 on the Emerging Stock Board, up from NT$54 a year earlier, Taipei Exchange data showed.
CALL FOR SUPPORT: President William Lai called on lawmakers across party lines to ensure the livelihood of Taiwanese and that national security is protected President William Lai (賴清德) yesterday called for bipartisan support for Taiwan’s investment in self-defense capabilities at the christening and launch of two coast guard vessels at CSBC Corp, Taiwan’s (台灣國際造船) shipyard in Kaohsiung. The Taipei (台北) is the fourth and final ship of the Chiayi-class offshore patrol vessels, and the Siraya (西拉雅) is the Coast Guard Administration’s (CGA) first-ever ocean patrol vessel, the government said. The Taipei is the fourth and final ship of the Chiayi-class offshore patrol vessels with a displacement of about 4,000 tonnes, Lai said. This ship class was ordered as a result of former president Tsai Ing-wen’s (蔡英文) 2018
‘SECRETS’: While saying China would not attack during his presidency, Donald Trump declined to say how Washington would respond if Beijing were to take military action US President Donald Trump said that China would not take military action against Taiwan while he is president, as the Chinese leaders “know the consequences.” Trump made the statement during an interview on CBS’ 60 Minutes program that aired on Sunday, a few days after his meeting with Chinese President Xi Jinping (習近平) in South Korea. “He [Xi] has openly said, and his people have openly said at meetings, ‘we would never do anything while President Trump is president,’ because they know the consequences,” Trump said in the interview. However, he repeatedly declined to say exactly how Washington would respond in
WARFARE: All sectors of society should recognize, unite, and collectively resist and condemn Beijing’s cross-border suppression, MAC Minister Chiu Chui-cheng said The number of Taiwanese detained because of legal affairs by Chinese authorities has tripled this year, as Beijing intensified its intimidation and division of Taiwanese by combining lawfare and cognitive warfare, the Mainland Affairs Council (MAC) said yesterday. MAC Minister Chiu Chui-cheng (邱垂正) made the statement in response to questions by Democratic Progressive Party (DPP) Legislator Puma Shen (沈柏洋) about the government’s response to counter Chinese public opinion warfare, lawfare and psychological warfare. Shen said he is also being investigated by China for promoting “Taiwanese independence.” He was referring to a report published on Tuesday last week by China’s state-run Xinhua news agency,
‘ADDITIONAL CONDITION’: Taiwan will work with like-minded countries to protect its right to participate in next year’s meeting, the foreign ministry said The US will “continue to press China for security arrangements and protocols that safeguard all participants when attending APEC meetings in China,” a US Department of State spokesperson said yesterday, after Beijing suggested that members must adhere to its “one China principle” to participate. “The United States insists on the full and equal participation of all APEC member economies — including Taiwan — consistent with APEC’s guidelines, rules and established practice, as affirmed by China in its offer to host in 2026,” the unnamed spokesperson said in response to media queries about China putting a “one China” principle condition on Taiwan’s
RSS